Pub Date : 2022-04-04DOI: 10.2174/1567205019666220404104854
Seong-Hi Park, Kuem-Sun Han
BACKGROUND Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are screened to distinguish whether cognitive decline in older adults is attributed to pathological causes rather than normal aging. OBJECTIVE The purpose of this review was to analyze the diagnostic performance of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in screening for MCI and AD. METHODS Electronic searches were performed on MEDLINE, EMBASE, CINAHL, and PsycArticles databases using the following keywords: dementia and ADAS-Cog. The Quality Assessment of Diagnostic Accuracy Studies-2 was used to checked the risk of bias in the diagnostic studies. RESULTS We reviewed 14 studies, including 3,875 patients who met the selection criteria. In 2,624 MCI patients from nine studies, the pooled sensitivity of ADAS-Cog was 0.80 (95% confidence interval [CI], 0.68-0.88), the pooled specificity was 0.84 (95% CI, 0.75-0.90), and the area under the curve of summary receiver-operating characteristic curves (SROC AUC) was 0.89 (SE = 0.03). In 2,517 AD patients from 10 studies, the pooled sensitivity and pooled specificity were 0.91 (95% CI, 0.86-0.95) and 0.93 (95% CI, 0.88-0.95) respectively, and the sROC AUC was 0.97 (SE = 0.01). Although sub-analyzed according to age and years of education, there was no significant difference in the predictive validity of the ADAS-Cog. CONCLUSION The ADAS-Cog has high predictive validity as a screening tool in both MCI and AD, but has better diagnostic performance in patients with AD. When early screening for AD is desired, ADAS-Cog is a first-stage screener that can be initially employed.
{"title":"Is the Alzheimer's Disease Assessment Scale-Cognitive Subscale useful in screening for mild cognitive impairment and Alzheimer's disease? A systematic review.","authors":"Seong-Hi Park, Kuem-Sun Han","doi":"10.2174/1567205019666220404104854","DOIUrl":"https://doi.org/10.2174/1567205019666220404104854","url":null,"abstract":"BACKGROUND\u0000Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are screened to distinguish whether cognitive decline in older adults is attributed to pathological causes rather than normal aging.\u0000\u0000\u0000OBJECTIVE\u0000The purpose of this review was to analyze the diagnostic performance of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in screening for MCI and AD.\u0000\u0000\u0000METHODS\u0000Electronic searches were performed on MEDLINE, EMBASE, CINAHL, and PsycArticles databases using the following keywords: dementia and ADAS-Cog. The Quality Assessment of Diagnostic Accuracy Studies-2 was used to checked the risk of bias in the diagnostic studies.\u0000\u0000\u0000RESULTS\u0000We reviewed 14 studies, including 3,875 patients who met the selection criteria. In 2,624 MCI patients from nine studies, the pooled sensitivity of ADAS-Cog was 0.80 (95% confidence interval [CI], 0.68-0.88), the pooled specificity was 0.84 (95% CI, 0.75-0.90), and the area under the curve of summary receiver-operating characteristic curves (SROC AUC) was 0.89 (SE = 0.03). In 2,517 AD patients from 10 studies, the pooled sensitivity and pooled specificity were 0.91 (95% CI, 0.86-0.95) and 0.93 (95% CI, 0.88-0.95) respectively, and the sROC AUC was 0.97 (SE = 0.01). Although sub-analyzed according to age and years of education, there was no significant difference in the predictive validity of the ADAS-Cog.\u0000\u0000\u0000CONCLUSION\u0000The ADAS-Cog has high predictive validity as a screening tool in both MCI and AD, but has better diagnostic performance in patients with AD. When early screening for AD is desired, ADAS-Cog is a first-stage screener that can be initially employed.","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":"1 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41956630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-30DOI: 10.2174/1567205019666220330144432
S. Lippa, J. Gill, T. Brickell, Vivian A. Guedes, L. French, R. Lange
BACKGROUND Traumatic brain injury (TBI) has been associated with increased likelihood of late-life dementia; however, the mechanisms driving this relationship are elusive. Blood-based biomarkers may provide insight into these mechanisms and serve as useful prognostic indicators of cognitive recovery or decline following a TBI. OBJECTIVE The aim of this study was to examine blood biomarkers within one year of TBI and explore their relationship with cognitive decline. METHODS Service members and veterans (n=224) without injury (n=77), or with history of bodily injury (n=37), uncomplicated mild TBI (n=55), or more severe TBI (n=55), underwent a blood draw and neuropsychological assessment within one year of their injury as part of a case-control study. A subsample (n=87) completed follow-up cognitive assessment. RESULTS In the more severe TBI group, baseline glial fibrillary acidic protein (p=.008) and ubiquitin C-terminal hydrolase-L1 (p=.026) were associated with processing speed at baseline, and baseline ubiquitin C-terminal hydrolase-L1 predicted change in immediate (R2Δ=.244, p=.005) and delayed memory (R2Δ=.390, p=.003) over time. In the mild TBI group, higher baseline tau predicted greater negative change in perceptual reasoning (R2Δ=.188, p=.033) and executive functioning (R2Δ=.298, p=.007); higher baseline neurofilament light predicted greater negative change in perceptual reasoning (R2Δ=.211, p=.012). CONCLUSION Baseline ubiquitin C-terminal hydrolase-L1 strongly predicted memory decline in the more severe TBI group, while tau and neurofilament light strongly predicted decline in the mild TBI group. A panel including these biomarkers could be particularly helpful in identifying those at risk for future cognitive decline following TBI.
{"title":"Blood Biomarkers Predict Future Cognitive Decline after Military-Related Traumatic Brain Injury.","authors":"S. Lippa, J. Gill, T. Brickell, Vivian A. Guedes, L. French, R. Lange","doi":"10.2174/1567205019666220330144432","DOIUrl":"https://doi.org/10.2174/1567205019666220330144432","url":null,"abstract":"BACKGROUND\u0000Traumatic brain injury (TBI) has been associated with increased likelihood of late-life dementia; however, the mechanisms driving this relationship are elusive. Blood-based biomarkers may provide insight into these mechanisms and serve as useful prognostic indicators of cognitive recovery or decline following a TBI.\u0000\u0000\u0000OBJECTIVE\u0000The aim of this study was to examine blood biomarkers within one year of TBI and explore their relationship with cognitive decline.\u0000\u0000\u0000METHODS\u0000Service members and veterans (n=224) without injury (n=77), or with history of bodily injury (n=37), uncomplicated mild TBI (n=55), or more severe TBI (n=55), underwent a blood draw and neuropsychological assessment within one year of their injury as part of a case-control study. A subsample (n=87) completed follow-up cognitive assessment.\u0000\u0000\u0000RESULTS\u0000In the more severe TBI group, baseline glial fibrillary acidic protein (p=.008) and ubiquitin C-terminal hydrolase-L1 (p=.026) were associated with processing speed at baseline, and baseline ubiquitin C-terminal hydrolase-L1 predicted change in immediate (R2Δ=.244, p=.005) and delayed memory (R2Δ=.390, p=.003) over time. In the mild TBI group, higher baseline tau predicted greater negative change in perceptual reasoning (R2Δ=.188, p=.033) and executive functioning (R2Δ=.298, p=.007); higher baseline neurofilament light predicted greater negative change in perceptual reasoning (R2Δ=.211, p=.012).\u0000\u0000\u0000CONCLUSION\u0000Baseline ubiquitin C-terminal hydrolase-L1 strongly predicted memory decline in the more severe TBI group, while tau and neurofilament light strongly predicted decline in the mild TBI group. A panel including these biomarkers could be particularly helpful in identifying those at risk for future cognitive decline following TBI.","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44681215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-18DOI: 10.2174/1567205019666220318092003
F. Neta, Francisco Emílio Simplício de Souza, André Lima Batista, Francisco Irochima Pinheiro, R. Cobucci, F. Guzen
BACKGROUND Conditions along the brain-gut-microbiota (BGM) axis can significantly contribute to the pathogenesis of Alzheimer's disease (AD). Evidence from animal studies indicates a role for probiotics in regulating mood, cognition, and stress response via the BGM axis. However, the effect of probiotics on AD needs to be better clarified in preclinical and clinical studies. METHOD We prepared this systematic review according to PRISMA. PubMed, Web of Science, Embase, and Virtual Health Library (VHL) were searched for original articles concerning the effects of probiotics in experimental AD. RESULTS Results were presented as a narrative synthesis according to the Synthesis Without Meta-analysis (SWiM) Guideline.Seventeen studies met the inclusion criteria. The results showed significant effects in the experimental models of AD treated with probiotics alone or in mixture form due to expressive improvements in cognitive tests. CONCLUSION Furthermore, in most of the included studies, it was possible to observe a reduction in inflammatory processes, an increase in the concentration of peptide hormones, insulin homeostasis in the brain, increased antioxidant enzymes, and a decrease in beta-amyloid deposition and tau hyperphosphorylation. Supplementation of probiotics seems to improve performance in cognitive tests and increase the concentration of substances capable of delaying the neurodegenerative process of AD in experimental models.
背景脑肠微生物群(BGM)轴上的条件可显著促进阿尔茨海默病(AD)的发病机制。来自动物研究的证据表明,益生菌通过BGM轴在调节情绪、认知和应激反应中发挥作用。然而,益生菌对AD的影响需要在临床前和临床研究中更好地阐明。方法根据PRISMA编制本系统综述。检索PubMed、Web of Science、Embase和虚拟健康图书馆(VHL)中关于益生菌在实验性AD中的作用的原创文章。结果根据无荟萃分析综合(SWiM)指南作为叙述性综合呈现。17项研究符合纳入标准。结果显示,由于认知测试中的表达改善,单独或混合使用益生菌治疗的AD实验模型具有显著效果。结论此外,在大多数纳入的研究中,可以观察到炎症过程减少,肽激素浓度增加,大脑中胰岛素稳态,抗氧化酶增加,β淀粉样蛋白沉积和tau过度磷酸化减少。在实验模型中,补充益生菌似乎可以提高认知测试的表现,并增加能够延缓AD神经退行性过程的物质的浓度。
{"title":"Effects of supplementation with probiotics in experimental models of Alzheimer's Disease: a systematic review of animal experiments.","authors":"F. Neta, Francisco Emílio Simplício de Souza, André Lima Batista, Francisco Irochima Pinheiro, R. Cobucci, F. Guzen","doi":"10.2174/1567205019666220318092003","DOIUrl":"https://doi.org/10.2174/1567205019666220318092003","url":null,"abstract":"BACKGROUND\u0000Conditions along the brain-gut-microbiota (BGM) axis can significantly contribute to the pathogenesis of Alzheimer's disease (AD). Evidence from animal studies indicates a role for probiotics in regulating mood, cognition, and stress response via the BGM axis. However, the effect of probiotics on AD needs to be better clarified in preclinical and clinical studies.\u0000\u0000\u0000METHOD\u0000We prepared this systematic review according to PRISMA. PubMed, Web of Science, Embase, and Virtual Health Library (VHL) were searched for original articles concerning the effects of probiotics in experimental AD.\u0000\u0000\u0000RESULTS\u0000Results were presented as a narrative synthesis according to the Synthesis Without Meta-analysis (SWiM) Guideline.Seventeen studies met the inclusion criteria. The results showed significant effects in the experimental models of AD treated with probiotics alone or in mixture form due to expressive improvements in cognitive tests.\u0000\u0000\u0000CONCLUSION\u0000Furthermore, in most of the included studies, it was possible to observe a reduction in inflammatory processes, an increase in the concentration of peptide hormones, insulin homeostasis in the brain, increased antioxidant enzymes, and a decrease in beta-amyloid deposition and tau hyperphosphorylation. Supplementation of probiotics seems to improve performance in cognitive tests and increase the concentration of substances capable of delaying the neurodegenerative process of AD in experimental models.","PeriodicalId":10810,"journal":{"name":"Current Alzheimer research","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2022-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46606531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}